[go: up one dir, main page]

IL166078A0 - Sustained-release tablet composition of pramipexole - Google Patents

Sustained-release tablet composition of pramipexole

Info

Publication number
IL166078A0
IL166078A0 IL16607804A IL16607804A IL166078A0 IL 166078 A0 IL166078 A0 IL 166078A0 IL 16607804 A IL16607804 A IL 16607804A IL 16607804 A IL16607804 A IL 16607804A IL 166078 A0 IL166078 A0 IL 166078A0
Authority
IL
Israel
Prior art keywords
pramipexole
sustained
release tablet
tablet composition
composition
Prior art date
Application number
IL16607804A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of IL166078A0 publication Critical patent/IL166078A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IL16607804A 2002-07-25 2004-12-30 Sustained-release tablet composition of pramipexole IL166078A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39844702P 2002-07-25 2002-07-25
US39842702P 2002-07-25 2002-07-25
US47951303P 2003-06-18 2003-06-18
PCT/US2003/023205 WO2004010997A1 (en) 2002-07-25 2003-07-25 Sustained-release tablet composition of pramipexole

Publications (1)

Publication Number Publication Date
IL166078A0 true IL166078A0 (en) 2006-01-15

Family

ID=31192087

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16607804A IL166078A0 (en) 2002-07-25 2004-12-30 Sustained-release tablet composition of pramipexole

Country Status (41)

Country Link
US (2) US20050226926A1 (xx)
EP (2) EP1531814B1 (xx)
JP (1) JP4700963B2 (xx)
KR (1) KR100712832B1 (xx)
CN (1) CN1313092C (xx)
AP (1) AP2201A (xx)
AR (1) AR040681A1 (xx)
AT (1) ATE406162T1 (xx)
AU (1) AU2003261241B2 (xx)
BR (1) BR0312960A (xx)
CA (1) CA2492854C (xx)
CR (1) CR7661A (xx)
CU (1) CU23440B7 (xx)
CY (1) CY1110408T1 (xx)
DE (1) DE60323235D1 (xx)
DK (1) DK1531814T3 (xx)
EA (2) EA009663B1 (xx)
EC (1) ECSP055568A (xx)
ES (1) ES2310673T3 (xx)
GE (1) GEP20074048B (xx)
HK (1) HK10777456A1 (xx)
HR (1) HRP20041235B1 (xx)
IL (1) IL166078A0 (xx)
IS (1) IS7623A (xx)
MA (1) MA27328A1 (xx)
ME (1) MEP52308A (xx)
MX (1) MXPA05001054A (xx)
MY (1) MY138846A (xx)
NO (1) NO334298B1 (xx)
NZ (1) NZ537790A (xx)
OA (1) OA13303A (xx)
PA (1) PA8578301A1 (xx)
PE (1) PE20040130A1 (xx)
PL (1) PL215587B1 (xx)
PT (1) PT1531814E (xx)
RS (1) RS51719B (xx)
SI (1) SI1531814T1 (xx)
TW (1) TWI347849B (xx)
UY (1) UY27912A1 (xx)
WO (1) WO2004010997A1 (xx)
ZA (1) ZA200500439B (xx)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305252A1 (en) * 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
MY142204A (en) * 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
CN1823091B (zh) 2003-07-11 2010-05-12 旭化成化学株式会社 功能性淀粉粉末
KR20070050081A (ko) * 2004-08-13 2007-05-14 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
RS52057B2 (sr) * 2004-08-13 2018-03-30 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
DE602004022205D1 (de) * 2004-09-09 2009-09-03 Psicofarma S A De C V Pharmazeutische zusammensetzung für die verzögerte freisetzung von hydralazin und ihre verwendung als unterstützung zur krebstherapie
EP1731514A1 (en) * 2005-06-02 2006-12-13 Sandoz AG Process for the preparation of Pramipexole
JP2009504748A (ja) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
KR20090021169A (ko) * 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) * 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
JP2010525018A (ja) * 2007-04-24 2010-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物
US20080299189A1 (en) * 2007-06-04 2008-12-04 Drugtech Corporation Controlled release dopamine agonist compositions
WO2009152041A2 (en) * 2008-06-09 2009-12-17 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2010148409A1 (en) * 2009-06-19 2010-12-23 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
EP2448411A4 (en) * 2009-07-02 2012-11-28 Supernus Pharmaceuticals Inc METHOD OF TREATING A NEUROLOGICAL DISORDER
WO2011037976A2 (en) * 2009-09-22 2011-03-31 Dr. Reddy's Laboratories Limited Pramipexole pharmaceutical formulations
EP2525786A2 (en) 2010-01-18 2012-11-28 Synthon BV Pramipexole extended release tablets
TR201001862A1 (tr) 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
JP2013526601A (ja) 2010-05-24 2013-06-24 ルピン・リミテッド プラミペキソールの徐放性製剤
KR101307334B1 (ko) * 2010-07-02 2013-09-12 주식회사 바이오파마티스 프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
WO2013034173A1 (en) 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2732812A1 (de) 2012-11-15 2014-05-21 Aristo Pharma GmbH Pramipexol-Retardtablettenformulierung
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
CN103520128B (zh) 2013-10-12 2018-08-21 石家庄杏林锐步医药科技股份有限公司 一种普拉克索的缓释片剂、制备方法及其用途
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
WO2018200387A1 (en) 2017-04-24 2018-11-01 Chase Therapeutics Corporation Compositions and method for treating depression
KR20200026920A (ko) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
CN109316466B (zh) * 2017-07-31 2022-04-05 深圳翰宇药业股份有限公司 一种盐酸普拉克索缓释制剂及其制备方法
CA3072994A1 (en) 2017-08-17 2019-02-21 Zi-Qiang Gu Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof
CN113876729B (zh) * 2021-11-11 2023-05-30 南通联亚药业股份有限公司 一种盐酸普拉克索缓释片剂及其制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15735A (en) * 1856-09-16 Improvement in harvesters
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja) 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
CH649215A5 (de) 1981-04-29 1985-05-15 Hoffmann La Roche Pharmazeutische praeparate.
SE8103843L (sv) 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
EP0186087B1 (de) 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4709712A (en) 1986-10-22 1987-12-01 Dermatalogical Products Of Texas Polycarboxylic acid polymer gels as protective agents
GB8828020D0 (en) 1988-12-01 1989-01-05 Unilever Plc Topical composition
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
HU210264B (en) 1989-06-09 1995-03-28 Upjohn Co Process for producing amines of condensed ring-systems containing nitrogen and pharmaceutical compositions containing them
GB9015822D0 (en) 1990-07-18 1990-09-05 Beecham Group Plc Compositions
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5431920A (en) 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
NZ513456A (en) * 1997-07-01 2003-02-28 Pfizer Sertraline acetate, L-lactate and L-aspartate, processes for their preparation and their uses in psychotic disorders
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
CA2211778A1 (en) * 1997-08-14 1999-02-14 Francois Carriere Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
GB9802201D0 (en) * 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
KR20010034588A (ko) * 1998-03-11 2001-04-25 피터 기딩스 조성물
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
DE19906290A1 (de) 1999-02-15 2000-08-17 Falk Pharma Gmbh Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EE05022B1 (et) * 1999-03-31 2008-06-16 Janssen Pharmaceutica N.V. Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
EP2090312A1 (en) 1999-07-01 2009-08-19 Pharmacia & Upjohn Company LLC (S,S) reboxetine for treating attention deficit disorder
AU5060499A (en) 1999-08-04 2001-03-05 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
US6387403B1 (en) 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
AU7620600A (en) 1999-09-30 2001-04-30 General Hospital Corporation, The Use of pramipexole as a treatment for cocaine craving
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2394222A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
US6467637B2 (en) 2000-01-27 2002-10-22 The York Group, Inc. Death care merchandising system
NZ520975A (en) 2000-02-24 2004-03-26 Upjohn Co New drug combinations containing a norepinephrine reuptake inhibitor and an antimuscarinic agent for treating nervous system disorders
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
ES2187249B1 (es) 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
SE0004671D0 (sv) 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
DE10138275A1 (de) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
BR0215262A (pt) 2001-12-20 2004-12-28 Pharmacia Corp Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
JP2005538105A (ja) 2002-07-25 2005-12-15 ファルマシア・コーポレーション 水不溶性ポリマーおよび水溶性の小孔形成物質からなる２層により被覆された固体剤形の製造方法
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2003224467A1 (en) 2003-03-11 2004-09-30 Korea United Pharm, Inc. Process for the preparing of hardcapsule formulation containing lansoprazole
CA2520321A1 (en) 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
US20050020589A1 (en) 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
KR20070050081A (ko) 2004-08-13 2007-05-14 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
RS52057B2 (sr) 2004-08-13 2018-03-30 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
WO2006046256A1 (en) 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
EP1901720A2 (en) 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
EP1901721A1 (en) 2005-06-23 2008-03-26 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
JP2009504748A (ja) 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2007090883A1 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
WO2007090882A2 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US20090041844A1 (en) 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
EP1886665A1 (en) 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system

Also Published As

Publication number Publication date
EP1531814B1 (en) 2008-08-27
NO20050093L (no) 2005-02-24
CU23440B7 (es) 2009-10-16
EA200500079A1 (ru) 2005-06-30
ES2310673T3 (es) 2009-01-16
MA27328A1 (fr) 2005-05-02
OA13303A (en) 2007-04-13
SI1531814T1 (sl) 2008-12-31
CN1313092C (zh) 2007-05-02
JP4700963B2 (ja) 2011-06-15
AU2003261241B2 (en) 2009-06-18
PT1531814E (pt) 2008-10-29
US20050226926A1 (en) 2005-10-13
AR040681A1 (es) 2005-04-13
KR20050062516A (ko) 2005-06-23
US8399016B2 (en) 2013-03-19
DK1531814T3 (da) 2008-10-13
GEP20074048B (en) 2007-02-26
MEP52308A (en) 2011-02-10
MXPA05001054A (es) 2005-04-08
RS20050059A (sr) 2007-08-03
HRP20041235A2 (en) 2005-06-30
EA200702187A1 (ru) 2008-06-30
WO2004010997A1 (en) 2004-02-05
CA2492854A1 (en) 2004-02-05
ATE406162T1 (de) 2008-09-15
CN1671382A (zh) 2005-09-21
ZA200500439B (en) 2006-08-30
PL215587B1 (pl) 2013-12-31
PE20040130A1 (es) 2004-03-06
EA009663B1 (ru) 2008-02-28
TW200418523A (en) 2004-10-01
AP2201A (en) 2011-01-24
US20100316710A1 (en) 2010-12-16
UY27912A1 (es) 2004-02-27
ECSP055568A (es) 2005-04-18
NO334298B1 (no) 2014-01-27
HRP20041235B1 (hr) 2013-07-31
JP2005538106A (ja) 2005-12-15
CR7661A (es) 2005-06-08
MY138846A (en) 2009-07-31
NZ537790A (en) 2005-10-28
BR0312960A (pt) 2005-06-14
PA8578301A1 (es) 2004-07-20
WO2004010997A8 (en) 2005-02-24
EP1987832A1 (en) 2008-11-05
HK10777456A1 (en) 2007-11-30
PL375696A1 (en) 2005-12-12
RS51719B (sr) 2011-10-31
AU2003261241A1 (en) 2004-02-16
KR100712832B1 (ko) 2007-04-30
IS7623A (is) 2004-12-29
CA2492854C (en) 2009-10-20
DE60323235D1 (de) 2008-10-09
CY1110408T1 (el) 2015-04-29
EP1531814A1 (en) 2005-05-25
TWI347849B (en) 2011-09-01
AP2005003205A0 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
TWI347849B (en) Sustained-release tablet composition of pramipexole
IL166079A0 (en) Sustained-release tablet comprising reboxetine
EG23458A (en) Set of elements for assemlying structures
IL166076A0 (en) Pramipexole once-daily dosage form
EP1549316A4 (en) HAMMER OF TFGbeta
AU2003236991A8 (en) Representations of processes
PL375784A1 (en) Use of erythopoietin
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
EP1562900A4 (en) POLYMORPH OF BICIFADINHYDROCHLORIDE
GB0221513D0 (en) Novel compounds and processes
AU2003262141A8 (en) Preperation of desloratatine
AU2003246098A8 (en) Oxamidination process of carbonyl compounds
AU2003298725A8 (en) Preparation of metallotexaphyrins
PL375437A1 (en) Synthesis of gatifloxacin
GB0225106D0 (en) Synthesis of 3 hydroxy-5 -steroids
GB0211949D0 (en) Novel compounds compositions and processes
AU2003217354A8 (en) Synthesis of sulfamidates
AU2003267944A8 (en) Novel trifluoromethylepinephrine compounds and methods of making and using thereof
PL356853A1 (en) Application of bacteriphages
GB0202358D0 (en) Synthesis of fluorinating agents
IL163778A0 (en) Processes for the synthesis of chloroadenosine andmethylthioadenosine
GB0227730D0 (en) Novel production of biocompounds
GB0229986D0 (en) Treatment of materials
GB0222015D0 (en) Means of assembly-bozz 2
SI1537210T1 (sl) Lazna oligonukleotidna inhibicija ekspresije CD40